Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients

Indian Journal of Pharmacology

Volumn 43, Issue 4, 2011, Pages 385-388

  Katsakiori, Paraskevi F ^a   Papapetrou, Eirini P ^b   Goumenos, Dimitrios S ^a   Nikiforidis, George C ^a   Flordellis, Christodoulos S ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CYP3A5; pharmacokinetics; renal transplantation; statin; tacrolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; AZATHIOPRINE; CHOLESTEROL; CREATINE KINASE; CREATININE; CYTOCHROME P450 3A5; EVEROLIMUS; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; SIMVASTATIN; TACROLIMUS;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DNA EXTRACTION; DRUG DISTRIBUTION; FEMALE; GENOTYPE; GRAFT RECIPIENT; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER FUNCTION; MALE; MYOPATHY; POLYMERASE CHAIN REACTION; SIDE EFFECT;

EID: 80053223435     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.83106     Document Type: Article

References (23)

1. Gresser U, Gathof BS. Atorvastatin: Gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Eur J Med Res 2004;9:1-17.
2. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.Clin Pharmacokinet 2002;41:343-70. (Pubitemid 34713089)
3. Bellosta S, Paoletti R, Corsini A. Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109Suppl23:III50-7. (Pubitemid 38786444)
4. Talbert RL. Safety issues with statin therapy. J Am Pharm Assoc (2003) 2006;46:479-88;quiz 488-90.
5. Frishman WH, Horn J. Statin-drug interactions: Not a class effect. Cardiol Rev 2008;16:205-12.
6. Mangravite LM, Krauss RM. Pharmacogenomics of statin response. Curr Opin Lipidol 2007;18:409-14. (Pubitemid 47051919)
7. Mück W, Neal DA, Boix O, Voith B, Hasan R, Alexander GJ. Tacrolimus/cerivastatin interaction study in liver transplant recipients. Br J Clin Pharmacol 2001;52:213-5. (Pubitemid 32863083)
8. Petsko GA. Pharmacogenomics arrives. Genome Biol 2004;5:108.
9. deJonge H, Kuypers DR. Pharmacogenetics in solid organ transplantation: Current status and future directions. Transplant Rev (Orlando) 2008;22:6-20. (Pubitemid 350131580)
10. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002;48:1668-71.
11. Tirelli S, Ferraresso M, Ghio L, Meregalli E, Martina V, Belingheri M, et al. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients. Med Sci Monit 2008;14:CR251-4. (Pubitemid 351679870)
12. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81. (Pubitemid 44908269)
13. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.Clin Pharmacokinet 2008;47:463-74. (Pubitemid 351861958)
14. Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, et al. Combined therapy with atorvastatin and calcineurin inhibitors: No interactions with tacrolimus.Am J Transplant 2005;5:2236-43. (Pubitemid 41648471)
15. Skalicka B, Kubanek M, Malek I, Vymetalova Y, Hoskova L, Podzimkova M, et al. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.J Heart Lung Transplant 2009;28:598-604.
16. Hurst FP, Neff RT, Jindal RM, Roberts JR, Lentine KL, Agodoa LY, et al. Incidence, predictors and associated outcomes of rhabdomyolysis after kidney transplantation.Nephrol Dial Transplant 2009;24:3861-6.
17. Thervet E, Legendre C, Beaune P, Anglicheau D. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005;6:37-47. (Pubitemid 40220669)
18. King BP, Leathart JB, Mutch E, Williams FM, Daly AK. CYP3A5 phenotypegenotype correlations in a British population [published erratum appears in Br J ClinPharmacol 2004;57:664].
19. Br J ClinPharmacol 2003;55:625-9.
20. Mourad M, Mourad G, Wallemacq P, Garrigue V, Van Bellingen C, Van Kerckhove V, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005;80:977-84. (Pubitemid 41552896)
21. Burckart GJ, Liu XI. Pharmacogenetics in transplant patients: Can it predict pharmacokinetics and pharmacodynamics? Ther Drug Monit 2006;28:23-30.
22. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ClinPharmacolTher 2004;75:101-9. (Pubitemid 38130122)
23. Renders L, Haas CS, Liebelt J, Oberbarnscheidt M, Schöcklmann HO, Kunzendorf U. Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. Br J Clin Pharmacol 2003;56:214-9. (Pubitemid 36981437)